Navigation Links
BioLife Solutions Granted European Biopreservation Patent

BOTHELL, Wash., Dec. 8 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has been granted a European patent for an application that includes claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. The patent titled, "Inclusion of Apoptotic Regulators in Solutions for Cell Storage at Low Temperature," was previously granted US patent protection.

Mike Rice, BioLife's chairman and CEO, noted that the new patent expands the protections of the Company's key intellectual property related to regulating the biologic process of apoptosis (programmed cell death) in response to the accumulated stress due to exposure to hypothermic and freezing temperatures. The new patent is a direct result of BioLife's ongoing effort to increase the value of its intellectual property portfolio and enable additional product and licensing revenue streams for BioLife, he added.

"We've repeatedly shown via numerous internal and customer validations that our products better protect cells and tissues from the harmful necrotic and apoptotic effects of hypothermic storage, freezing, and thawing, and as a result, can extend the shelf life and improve the post preservation recovery, viability, and functional yield of both biologic source material as well as isolated cells," Rice said, adding that the Company has submitted several additional patent applications during 2008.

About BioLife Solutions, Inc.:

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

     Media Relations:                              Investor Relations:
     Len Hall                                      Matt Clawson
     Allen & Caron Inc                             Allen & Caron Inc
     (949) 474-4300                                (949) 474-4300                  

SOURCE BioLife Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
2. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
3. BioLife Solutions Credit Facility Increased to $9 Million
4. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
5. BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation
6. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
7. BioLife Solutions Expands Scientific Advisory Board
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. TRIDELITY Display Solutions Partners With Two Of The World's Leading Imaging Software Companies
10. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Whitehouse Laboratories ... Laboratory. The new stand-alone facility will be strictly dedicated to basic USP 61, ... and existing clients the chance to have complete chemistry and micro testing performed by ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
(Date:11/23/2015)... Nov. 23, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the second ... September 30, 2015. --> ... , Revenues for the second quarter of fiscal 2016 ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):